Nagarajan Priyadharsini
Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
J Cutan Pathol. 2020 Apr;47(4):418-420. doi: 10.1111/cup.13640. Epub 2020 Jan 14.
To distinguish keratoacanthomas from squamous cell carcinomas remains a diagnostic challenge in dermatopathology. Several immunohistochemical and cytogenetic markers have been evaluated; however, so far there has been no unequivocal evidence supporting practical application of any of these markers. Recent studies have evaluated the composition of tumor-associated immune infiltrate, in particular the number and distribution of CD123-positive plasmacytoid dendritic cells in making this distinction; but these cells also do not appear to be a consistent biomarker in distinguishing keratoacanthoma from squamous cell carcinoma.
在皮肤病理学中,区分角化棘皮瘤和鳞状细胞癌仍然是一项诊断挑战。已经评估了几种免疫组织化学和细胞遗传学标志物;然而,到目前为止,尚无明确证据支持这些标志物中的任何一种的实际应用。最近的研究评估了肿瘤相关免疫浸润的组成,特别是在进行这种区分时CD123阳性浆细胞样树突状细胞的数量和分布;但这些细胞在区分角化棘皮瘤和鳞状细胞癌时似乎也不是一致的生物标志物。